Inhibitors of advanced glycation end products

A compound of the formula,

• or a pharmaceutically acceptable salt thereof, wherein
• X is N or N—O;
• G is —H;
• A is of the formula,
• wherein
• Y is N or N-oxide;
• and
• ring C is:
• (i) monocyclic;
• (ii) saturated;
• and
• (iii) contains 1 or 2 total heteroatoms, and 5 or 6 total atoms, wherein
• the remaining heteroatom moiety is O, S, or NRN1, and the carbon atoms are each optionally substituted with one or two RC wherein
• RN1 is —H, -oxide, —(C1-C6)alkyl, —(C2-C6)alkenyl, —(C1-C6)alkynyl, —(C1-C6)haloalkyl, or —(C1-C6)alkanoyl;
• each RC is independently —Z1-M-Z2—RZ, wherein
• Z1, M and Z2 are absent, and
• RZ is —H, —(C1-C6)alkyl, —(C2-C6)alkenyl, —(C1-C6)alkynyl, or —(C1-C6)haloalkyl, —(C3-C8)cycloalkyl, —(C1-C6)alkylaryl, -heterocycle, -aryl, or -heteroaryl;
• B is imidazolyl wherein each carbon atom is substituted by R3, wherein
• each R3 is independently RZ3, wherein
• RZ3 is —H, —(C1-C6)alkyl, —(C1-C6)haloalkyl, —(C3-C8)cycloalkyl, —(C1-C6)alkylaryl, -heterocycle, -aryl, or -heteroaryl;
• and
• R2, and R6 are independently —H, -halogen, —NO2, —CN, or RZ6 wherein RZ6 is —(C1-C6)alkyl or —(C1-C6)haloalkyl.